What's Behind Intuitive Surgical Inc's Revenue Miss?

Intuitive misses already-lowered Q1 expectations by a wide amount.

Apr 11, 2014 at 2:30PM

If surgical robot pioneer Intuitive Surgical (NASDAQ:ISRG) is going to keep its heady med-tech growth stock multiple, it has to do better than this. After logging just 4% revenue growth in 2013, Intuitive's announcement of a 24% drop to start 2014 is certainly not a step in the right direction. Some of the trouble may well be from transitory issues like weather and delays tied to hospitals awaiting new product rollouts, but Wall Street is not a forgiving place when high multiple growth stories stop delivering that growth.

The system shortfall seems explainable...
Intuitive Surgical warned the street that first-quarter revenue fell 24%, about 14% worse than the average sell-side estimate. Excluding deferrals tied to a system trade-out program, the revenue decline was more on the order of 19%, with the miss more on the order of 9%.

System sales were clearly a major component of the miss, as system revenue fell 59% in the first quarter (or 49% on an adjusted basis). U.S. system sales fell by more than half on a unit basis (45 versus 115). Anticipation of the new Xi system could have been behind some of this, but management also claimed that shifting U.S. hospital capital spending priorities with the Affordable Care Act was also a significant factor. I have my doubts about this, but reports from companies like Hologic, Stryker, GE, and Philips in the coming weeks should add some color to the hospital capital spending environment.

The procedures shortfall not so much
Capital equipment sales can be squirrelly, but the relative weakness in procedure volume growth is a little more problematic. Instrument and accessories sales declined 2% in the first quarter, with procedure volume growth of 7%. That was about 3% weaker than the sell-side expected, as well as a notable deceleration from the 12% year-over-year procedure volume growth in the fourth quarter.

U.S. gynecological procedure volume fell by low single digits, and it has to be asked whether the negative press about complication rates is starting to impact utilization. Neither Johnson & Johnson (NYSE:JNJ) nor Covidien (NYSE:COV) typically give mid-quarter updates, nor do they address specific procedure volumes (like gynecological procedures). That said, if these surgical business show the same sort of mid-to-high single-digit growth they've been reporting, it doesn't reflect so well on Intuitive's momentum.

The new Xi system looks like a winner
Intuitive did recently introduce a new system, the Xi, that has some real promise. This boom-mounted system uses very different architecture than the Si and Si-e systems, and it offers important advantages for general surgery like multi-quadrant capabilities and single port surgery (in the brochure, but not yet approved).

At a SAGES meeting that was pretty quiet for Johnson & Johnson and Covidien, Intuitive's Xi definitely got some attention. It is unlikely this system is going to replace the Si or Si-e, rather most hospitals will buy it to augment their existing robotic surgery programs and use it in more complicated cases.

Single port surgery is still an area where Johnson & Johnson and Covidien have a meaningful edge on Intuitive, but Xi could close that gap and drive more general and colorectal surgeries from Johnson & Johnson or Covidien tools to Intuitive Surgical. Johnson & Johnson, Covidien, and Stryker have all introduced single port tools that are considerably cheaper than Intuitive's approach, but there are familiar advantages to Intuitive's approach, including blood loss, recuperation times, and converting open procedures that otherwise could not be performed laparoscopically. With volumes in traditionally strong markets like prostate and hysterectomy having slowed so much, expanding the utility of the platform and gaining share in other procedures is an essential part of the Intuitive growth story.

The bottom line
If management can navigate the company through this rough patch and start driving adoption in under-penetrated surgical applications like general surgery, colorectal, and cardiac, the Street will forget about this rocky quarter. With Intuitive Surgical shares trading just below an EV/revenue of 8 times (a common multiple for high-growth med-tech names), it's hard to argue the stock isn't getting the benefit of the doubt.

Six stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently, one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his six carefully chosen picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Stephen D. Simpson, CFA, has no position in any stocks mentioned. The Motley Fool recommends Covidien, Intuitive Surgical, and Johnson & Johnson. The Motley Fool owns shares of Intuitive Surgical and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers